Agnc Investment Corp
Change company Symbol lookup
Select an option...
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
FONR Fonar Corp
WBRRFX BlackRock Russell 2000 Growth Index Fund
WSM Williams-Sonoma Inc
BLK BlackRock Inc
TSEM Tower Semiconductor Ltd
Go

Company profile

AGNC Investment Corp., formerly American Capital Agency Corp., is a real estate investment trust. The Company invests in agency residential mortgage-backed securities on a leveraged basis. Its investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by a government-sponsored enterprise, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac), or by the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) (collectively, GSEs). Its agency securities include agency residential mortgage-backed securities (Agency RMBS) and to-be-announced forward contracts (TBAs). Its Non-Agency Securities include credit risk transfer securities (CRT), non-agency residential mortgage-backed securities (Non-Agency RMBS) and commercial mortgage-backed securities (CMBS).

Closing Price
$14.03
Day's Change
-0.08 (-0.57%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.23
Day's Low
14.01
Volume
(Average)
Volume:
5,978,005

10-day average volume:
5,470,346
5,978,005

Multiple Sclerosis Drugs Market Worth $40.66 Bn at 7.1% CAGR; Industry Bigwigs Such as Novartis and Biogen to Focus on Introducing Cost-Effective MS Treatments: Fortune Business Insights(TM)

7:56 am ET August 24, 2020 (Globe Newswire) Print

The global multiple sclerosis drugs market size is projected to reach USD 40.66 billion by 2027, exhibiting a CAGR of 7.1% during the forecast period.

High prevalence of multiple sclerosis (MS) worldwide will be the primary factor driving the growth of this market, states Fortune Business Insights(TM) in its report, titled "Multiple Sclerosis Drugs Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2020-2027".

MS is a widespread degenerative neurological condition among young adults around the world. According to the Multiple Sclerosis Trust, approximately 2.5 million people worldwide are suffering from MS, with a higher number of women getting affected with the condition than men. In the UK, Public Health England, the UK government's health agency, found that between 2018 and 2020, the number of MS patients rose to 131,720.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

In the US, on the other hand, data from the National Multiple Sclerosis Society revealed that nearly 1 million people in the US are living with MS. Increasing incidence of this condition, therefore, is expected to surge the MS drugs market growth.

Key Industry Developments:

-- May 2020: Bristol Myers Squibb announced that its Zeposia drug, an oral medication for treating relapsing multiple sclerosis in adult patients received approval from the European Commission (EC). The marketing authorization from the EC will enable the company to broaden its presence in Europe.

-- March 2019: The US FDA gave its nod to Mayzent (siponimod), developed by Novartis to treat adults with relapsing forms of MS. The treatment will be able to treat relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) with active disease.

The report states that the value of the global market stood at USD 25.00 billion in 2019 and also provides the following:

-- Quantitative insights on the market values (size, share, revenue, etc.);

-- Qualitative analysis of the factors driving the market growth;

-- Thorough study of the market restraints;

-- Detailed examination of the market segments; and

-- Comprehensive assessment of the regional developments and competitive landscape of the market.

The global economy has plunged into turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, and some are in serious trouble. The healthcare industry is experiencing mixed impact of this pandemic. Navigating through these challenging times is a mammoth task and to aid you in your journey, Fortune Business Insights(TM) aims at equipping your business with the most comprehensive market intelligence, collated and analyzed by our expert and experienced research team.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Market Driver:

Availability of Monoclonal Antibodies for MS Treatment to Favor Market Growth

Monoclonal antibodies, as the name suggests, are clones of a specific antibody, which are developed as multiple sclerosis drug treatments. Their most notable feature is that they can tailor the immune system response to MS by binding to specific, targeted proteins on the body's normal cells.

Thus, these antibody treatments can be designed to deliver a highly specific effect in a patient. More importantly, there is growing availability of monoclonal antibodies, with some treatments being more widely used than others. For instance, Roche's Ocrevus antibody, which binds to and destroys B-cells, has been extensively adopted as an MS treatment since it received FDA approval in 2017.

Regional Analysis:

Healthy Awareness about MS to Feed Market Growth in North America

North America boasted a market size of USD 14.74 billion in 2019 on account of widespread awareness about MS and its treatments. In the US, government bodies such as the Multiple Sclerosis Association of America conducts educational drives during the month of March, which is recognized as the Multiple Sclerosis Awareness Month in the country.

Europe is expected to hold a prominent position in the multiple sclerosis drugs market share during the forecast period owing to supportive health reimbursement policies. In Asia Pacific, the market is anticipated to perform remarkably well as pharmaceutical companies are aggressively expanding their distribution networks across the region.

Quick Buy - Multiple Sclerosis Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100386

List of Key Players Covered in the Multiple Sclerosis Drugs Market Report:

-- Bristol-Myers Squibb Company (New York, U.S.)

-- Sanofi (Paris, France)

-- Novartis AG (Basel, Switzerland)

-- Pfizer Inc. (New York, U.S.)

-- Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)

-- Merck & Co., Inc. (New Jersey, U.S.)

-- F. Hoffmann-La Roche Ltd. (Basel, Switzerland)

-- Biogen (Massachusetts, U.S.)

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/multiple-sclerosis-drugs-market-100386

Multiple Sclerosis Drugs Market Segmentations:

By Drug Class

? Immunomodulators

? Immunosuppressants

? Interferons

? Others

By Route of Administration

? Oral

? Injection

o Intramuscular

o Subcutaneous

o Intravenous

By Distribution Channel

? Hospital Pharmacy

? Retail Pharmacy

? Online Pharmacy

By Geography

? North America (the U.S. and Canada)

? Europe (the U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

? Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

? Latin America (Brazil, Mexico, and Rest of Latin America)

? The Middle East & Africa (GCC, South Africa, and Rest of the Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/multiple-sclerosis-drugs-market-100386

Have a Look at Related Reports:

Neurodegenerative Diseases Drugs Market Share and Global Trend By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists), By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA)), By Route of Administration(Oral, Injection, Transdermal) By End User(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026

Immunology Market Share and Global Trend By Drug Class ( Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibody (pAb) ), By Disease Indication ( Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection ), By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Geography Forecast till 2025

Diabetes Treatment Devices Market Share and Global Trend By Product (Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, Others), By Distribution Channel (Institutional Sales (Hospitals, Clinics), Retail Sales (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)) & Geography Forecast till 2026

Diabetes Devices Market Share and Global Trend By Product (Monitoring Devices, Treatment Devices), By Distribution Channel (Institutional Sales, Retail Sales) and Geography Forecast till 2026

Cardiac Pacemakers Market Share and Global Trend By Product (Single Chamber Pacemakers, Dual Chamber Pacemakers, Cardiac Resynchronization Therapy-Pacemakers (CRT-P)), By End User (Hospitals & Clinics, Ambulatory Surgery Centers and Others) & Geography Forecast till 2026

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/multiple-sclerosis-drugs-market-9105

https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.